X T L Biopharmaceuticals Ltd banner

Intrinsic Value

XTLB latest financial reports are more than 3 years old.
XTLB doesn't have a meaningful market cap.

The intrinsic value of X T L Biopharmaceuticals Ltd (XTLB) under the Base Case is 1.72 USD per share. Compared with the current market price of 1.48 USD, the stock appears Undervalued by 14% .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

XTLB Intrinsic Value
$1.72
Undervaluation 14%
Intrinsic Value
Price $1.48
Alert me when XTLB is below its intrinsic value
Today $1.37 · 7.3% below the current price

XTLB is cheaper than usual. This is its cheapest valuation in the past 5 years.

Alternatives to XTLB

Fundamental Analysis

What X T L Biopharmaceuticals Does

Biotechnology Health Care

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process.

Headquarters
Israel IL
Employees
33
IPO date
Sep 1, 2000
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue XTLB Research

Decided on X T L Biopharmaceuticals? Get an email when XTLB reaches the price you’d buy at. Free with an account.

Other X T L Biopharmaceuticals listings

What is the Intrinsic Value of one XTLB stock?

The intrinsic value for X T L Biopharmaceuticals Ltd (XTLB) under the Base Case is 1.72 USD.

Is XTLB stock undervalued or overvalued?

Compared with the current market price of 1.48 USD, the stock appears Undervalued by 14% .

How reliable are our estimates? See how past valuations played out
Back to Top